Sagimet Biosciences Inc. SGMT
We take great care to ensure that the data presented and summarized in this overview for Sagimet Biosciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SGMT
Top Purchases
Top Sells
About SGMT
Insider Transactions at SGMT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 23
2024
|
George Kemble Executive Chairman |
SELL
Open market or private sale
|
Direct |
23,625
-16.6%
|
$70,875
$3.17 P/Share
|
|
Jul 19
2024
|
George Kemble Executive Chairman |
SELL
Open market or private sale
|
Direct |
14,062
-8.99%
|
$42,186
$3.1 P/Share
|
|
Jul 19
2024
|
Elizabeth Rozek General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
10,914
-6.37%
|
$32,742
$3.1 P/Share
|
|
Jul 19
2024
|
Eduardo Bruno Martins Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,357
-9.33%
|
$25,071
$3.1 P/Share
|
|
Mar 26
2024
|
David Happel President & CEO |
BUY
Open market or private purchase
|
Direct |
12,100
+1.86%
|
$60,500
$5.27 P/Share
|
|
Jan 29
2024
|
Scott D Sandell > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
267,947
+50.0%
|
-
|
|
Jan 29
2024
|
Scott D Sandell > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,110,950
-61.04%
|
-
|
|
Jan 29
2024
|
New Enterprise Associates 13 LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
850,000
-22.08%
|
-
|
|
Jan 29
2024
|
Nea Partners 13, Limited Partnership > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
260,950
-100.0%
|
-
|
|
Jan 29
2024
|
Nea Partners 13, Limited Partnership > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
260,950
+50.0%
|
-
|
|
Jan 29
2024
|
Nea Partners 13, Limited Partnership > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
850,000
-22.08%
|
-
|
|
Jan 29
2024
|
Forest Baskett > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
272,250
+50.0%
|
-
|
|
Jan 29
2024
|
Forest Baskett > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,110,950
-61.04%
|
-
|
|
Jan 29
2024
|
Patrick J Kerins > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
13,139
+50.0%
|
-
|
|
Jan 29
2024
|
Patrick J Kerins > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,110,950
-61.04%
|
-
|
|
Jan 29
2024
|
Patrick J Kerins > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
260,950
+50.0%
|
-
|
|
Dec 07
2023
|
David Happel President & CEO |
BUY
Open market or private purchase
|
Direct |
1,600
+0.25%
|
$6,400
$4.1 P/Share
|
|
Nov 17
2023
|
Eduardo Bruno Martins Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
89,570
+50.0%
|
-
|
|
Nov 17
2023
|
David Happel President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
624,910
+49.98%
|
-
|
|
Nov 17
2023
|
George Kemble Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
150,750
+49.08%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.09M
Shares
From
5
Insiders
| Other acquisition or disposition | 1.08M shares |
|---|---|
| Open market or private purchase | 13.7K shares |
Sell / Disposition
5.35M
Shares
From
8
Insiders
| Other acquisition or disposition | 5.29M shares |
|---|---|
| Open market or private sale | 57K shares |